Navigation Links
West to Host 2008 First Quarter Conference Call
Date:4/24/2008

LIONVILLE, Pa., April 24 /PRNewswire-FirstCall/ -- West Pharmaceutical Services, Inc. (NYSE: WST) announced today that it will release 2008 first quarter financial results before the market opens on Thursday, May 1, 2008 and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call please dial (888) 790-3758 or (210) 839-8398. The passcode is WST.

A live broadcast of the conference call will be available at the Company's web site, http://www.westpharma.com, in the "Investor" section. Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.

An online archive of the broadcast will be available at the site two hours after the live call and will be available through Thursday, May 15, 2008, by dialing (800) 704-0508 or (402) 220-0326 and entering conference ID# 4320429.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at http://www.westpharma.com.

Contacts: Investors and Financial Media:

West
'/>"/>

SOURCE West Pharmaceutical Services, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Digirad Corporation Reports Financial Results for First-Quarter 2008
2. STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call
3. Zimmer Holdings, Inc. Reports First Quarter Financial Results
4. The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
5. Cambrex to Announce First Quarter 2008 Financial Results on May 1, 2008
6. Harold P. Freeman Patient Navigation Institute Completes First Trainings and Certifications
7. Aflac Incorporated Announces First Quarter Results, Declares Second Quarter Cash Dividend
8. NightHawk Radiology Holdings, Inc. to Host Conference Call to Discuss First Quarter 2008 Earnings Results
9. NIOXIN(R) Research Laboratories First to Market HairDX Genetic Test for Womens Hair Loss
10. RAI to Webcast First Quarter 2008 Earnings Conference Call
11. American Heart Association Launches First of New Journals - Circulation: Arrhythmia and Electrophysiology Premieres
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market 2Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 1Solution to PREVENT Novel H1N1 28Swine Flu 29 From Closing Down Schools 21 55627 2Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 1Congressman Schock Gets Health Care Reform Message In A Bottle From AARP 55623 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 1Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 2Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 3Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy 4916 4